SCHEMBL3529679

SCHEMBL3529679

C=C1[C@H](CO)C/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@H]1O

nearest known ligand 0.87

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ VDR P11473 8/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dp001 SCHEMBL12332637 0.93 VDR (0.81) VDR
Dp001 SCHEMBL12932256 0.93 VDR (0.81) VDR
Dp001 SCHEMBL15371114 0.93 VDR (0.81) VDR
Dp001 SCHEMBL18470321 0.93 VDR (0.81) VDR
Dp001 SCHEMBL10307542 0.93 VDR (0.81) VDR
Dp001 SCHEMBL8303273 0.93 VDR (0.81) VDR
Dp001 SCHEMBL19988220 0.93 VDR (0.81) VDR
Dp001 SCHEMBL15371106 0.93 VDR (0.81) VDR
Dp001 SCHEMBL21206294 0.93 VDR (0.81) VDR
Dp001 SCHEMBL29645040 0.93 VDR (0.81) VDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222635-A2 NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING Abbott Laboratories (US) 2010-09-01 — — EP claimed
WO-2009067578-A2 NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING ABBOTT LABORATORIES (US) 2009-05-28 — — WO claimed
US-8377913-B2 Vitamin D receptor activators and methods of making ABBVIE INC. (US) 2013-02-19 — — US disclosed
US-8377913-B2 Vitamin D receptor activators and methods of making ABBVIE INC. (US) 2013-02-19 — — US disclosed
US-8377913-B2 Vitamin D receptor activators and methods of making ABBVIE INC. (US) 2013-02-19 — — US disclosed
EP-2222635-A2 NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING Abbott Laboratories (US) 2010-09-01 — — EP disclosed
WO-2009067578-A2 NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING ABBOTT LABORATORIES (US) 2009-05-28 — — WO disclosed
WO-2009067578-A2 NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING ABBOTT LABORATORIES (US) 2009-05-28 — — WO disclosed
US-20090131379-A1 VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING ABBOTT LABORATORIES (US) 2009-05-21 — — US disclosed
US-20090131379-A1 VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING ABBOTT LABORATORIES (US) 2009-05-21 — — US disclosed
US-20090131379-A1 VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING ABBOTT LABORATORIES (US) 2009-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131379-A1 VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING VDR, CYP2R1, CYP24A1 VDR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback